This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Virtanen, M.
Right arrow Articles by Heinonen, O. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Virtanen, M.
Right arrow Articles by Heinonen, O. P.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Mumps
Measles
Rubella

PEDIATRICS Vol. 106 No. 5 November 2000, p. e62

ELECTRONIC ARTICLE:
Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination

Received Mar 29, 2000; accepted May 30, 2000.

Martti Virtanen*, Dagger , Heikki PeltolaDagger , §, Mikko Paunioparallel , and Olli P. Heinonenparallel

From the * National Research and Development Center for Welfare and Health; Dagger  National Public Health Institute; § Helsinki University Central Hospital, Hospital for Children and Adolescents; and the parallel  Department of Public Health, University of Helsinki, Helsinki, Finland.

Objective.  Revaccination policies adopted in many countries to control measles have raised various safety issues including those concerning the second vaccine dose. We performed a prospective, double-blind, crossover trial among twins receiving a measles-mumps-rubella (MMR) vaccine.

Study Design.  The study comprised 1162 monozygous and heterozygous twins, each of whom randomly received placebo and then vaccine, or vice versa, 3 weeks apart, at 14 to 83 months of age. Most of the oldest children had previously been vaccinated against measles, and one half of the remainder of children had had the disease. Symptoms and signs were recorded daily on structured forms. Statistical methods included a complex analysis of the vaccine attributability of the symptoms and conditional logistic regression.

Results.  Vaccination-attributable events occurred in 6% overall. At 14 to 18 months of age, reactions developed between days 6 and 14, peaking at day 10. The clearest vaccine-attributable effect was fever exceeding 101.3 °F (38.5°C; odds ratio: 3.28; 95% confidence interval: 2.23-4.82; P < .001), but the same trend was found for rash, arthralgia, conjunctivitis, staying in bed, drowsiness, and irritability. At 6 years of age, systemic reactions occurred 5 to 15 times less frequently, only arthralgia being associated with vaccination. Zygocity, gender, history of allergy, or infections did not modify reactions. Instead, respiratory symptoms developed within days postinjection to a level of 15% to 20% without subsequent decline and with no difference between vaccinees and placebo recipients.

Conclusion.  Vaccination was avoided during infections, but many small children became mildly ill within a week or so with no relation to vaccination (the healthy vaccinee effect). MMR vaccine was virtually nonreactogenic when given at 6 years of age. vaccine, measles, mumps, rubella, reactogenicity, adverse events, zygocity, healthy vaccinee effect. .




This article has been cited by other articles:


Home page
 PediatricsHome page
N. P. Klein, M. L. Massolo, J. Greene, C. L. Dekker, S. Black, G. J. Escobar, and for the Vaccine Safety Datalink
Risk Factors for Developing Apnea After Immunization in the Neonatal Intensive Care Unit
Pediatrics, March 1, 2008; 121(3): 463 - 469.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. J. Hambidge, J. M. Glanz, E. K. France, D. McClure, S. Xu, K. Yamasaki, L. Jackson, J. P. Mullooly, K. M. Zangwill, S. M. Marcy, et al.
Safety of Trivalent Inactivated Influenza Vaccine in Children 6 to 23 Months Old
JAMA, October 25, 2006; 296(16): 1990 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
E Miller, N Andrews, A Grant, J Stowe, and B Taylor
No evidence of an association between MMR vaccine and gait disturbance
Arch. Dis. Child., March 1, 2005; 90(3): 292 - 296.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
MMR vaccine - how effective and how safe?
DTB, April 1, 2003; 41(4): 25 - 29.
[Abstract] [Full Text] [PDF]